Create Account

Clinical trials determine if products work and are safe

Unlike many supplement brands that don’t test their products, Bonafide prioritizes safety and effectiveness by requiring clinical testing for all products. This approach gives customers and healthcare providers peace of mind knowing that our claims are supported by rigorous evidence

Over

13,000

women have participated in Bonafide clinical studies and surveys †

35+ clinical trials and counting†

Clairvee® relieves vaginal odor, itching, and discharge in women without an infection in just 15 days with continued relief over 6 months¹⁻²

Clairvee is a vaginal probiotic taken orally, 
1 capsule per day for 15 days each month.

In a randomized, double-blind, placebo-controlled trial of 40 symptomatic patients without an infection on culture (nugent score of 4-6)

In an open-label trial of women with moderate-to-severe vaginal odor and no known infection¹

2 weeks

0% 25% 50% 75% 100%

74% of women reported a reduction in vaginal odor at 2 weeks

6 months

0% 25% 50% 75% 100%

100% of women reported a reduction in vaginal odor at 6 months

% of women reporting a reduction in odor

In the same study, 93% of women studied reported that they prefer Clairvee to other OTC products for vaginal symptoms¹

In a separate study, 75% of women reported improvements in vaginal itching and discharge vs. placebo in 15 days²

Revaree®, made from hyaluronic acid, relieves vaginal dryness with no hormonal effect.³

Revaree is a vaginal suppository, inserted into the vagina 2-3 times per week.

In a survey of more than 3,000 women, 96% of women plan to continue using Revaree.⁵

Relizen® significantly reduces frequency and intensity of hot flashes without hormones.*⁶

Relizen is taken orally, 2 tablets per day for 30 days each month.

In a separate survey of more than 4,900 women, 85% reported they plan to continue taking Relizen.⁸

Ristela® significantly improves sexual function across all stages of a women's life.*⁹⁻¹¹

Ristela is taken orally, 2 tablets per day for 30 days each month.

In three separate clinical studies, Ristela was shown to significantly improve Female Sexual Function Index (FSFI) scores after 2 months ⁹⁻¹¹

Serenol™ significantly reduces irritabillity, mood swings, uneasiness, and overall PMS severity*¹³

Serenol is taken orally, 2 tablets per day for 30 days each month.

In a separate survey of more than 500 women, 75% experienced relief within 3 months and 82% reported that they plan to continue using Serenol¹⁴

Silvessa® improves the health and appearance of hair and skin affected by estrogen decline during menopause.*¹⁵⁻¹⁷

Silvessa capsule is taken orally, 1 capsule per day for 30 days each month. Silvessa serums are applied topically, 2 droplets for hair and 2 pumps for skin per day.

In the same study, 100% of women told us they were satisfied with how healthy their facial skin looked.¹⁵⁻¹⁶

The gold standard in clinical trials

We use the gold standard of product testing: double-blinded placebo-controlled trials. Neither the participants nor the study team know who received the placebo or the supplement.

This rigorous research method is used to provide reliable and unbiased evidence of our product's effectiveness and safety. It helps healthcare providers make informed decisions about patient treatment and gives consumers confidence in the quality of the products they purchase.

Join our participant community

Our Bonafide research team is passionately committed to developing new formulations to further support women’s health. We invite you to join our participant community and discover how you can contribute to the testing of new products that address menopausal symptoms.




As a participant, you contribute to advancing women’s health research and gain an opportunity to access new innovative products before they come to market. Help us make a difference in the lives of countless women.

Join our community and start participating

Bonafide difference

* These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

  • † Clinical trials were either conducted on Bonafide products or a key ingredient contained within Bonafide products.

  • ¹ Results from an open-label clinical study.
    ² Russo R, Edu A, De Seta F. Arch Gynecol Obstet. 2018; 298(1):139-145.

  • ³ Liu SB, et al. Gynecol Endocrinol. 2015;31:208-213. Preclinical study.
    ⁴ Chen J, et al. J Sex Med. 2013:10:1575-1584. Results based on Revaree's main ingredient, Hyaluronic Acid.
    ⁵ Dweck A, et al. J Sex Med. 2022;19(Supplement 3):S26.

  • ⁶ Winther K, et al Climateric 205;8:162-170
    ⁷ Elia D, Mares P. Genesis. 2008;135:12-15.
    ⁸ Bernsley D, Sylla S, Komorowski J. Menopause. 2021;28(12):P-4.

  • ⁹ Bottari A, et al. Panminerva Med. 2012;54:3-9. 8-week, single-blinded trial in 83 post-menopausal women ages 45 to 55.
    ¹⁰ Stanislavov R and Rohdewald P. J Women's Health Care. 2014;3:1-6. 8-week, randomized, double-blind, placebo-controlled study conducted in 80 women ages 40-50.
    ¹¹ Bottari A, et al. Panminerva Med. 2012;54:3-9. 8-week, single-blinded trial in 83 post-menopausal women ages 45 to 55.
    ¹² Kellog Spadt S, et al. Effects of Ristela supplementation on female sexual satisfaction: an open-label trial. Menopause. 2019:26(12):1467-1468.

  • ¹³ Winther K. Hedman C., Curr Ther Res Clin Exp. 2002;63(5):344-353.
    ¹⁴ Results are from an optional, rolling online survey, conducted from July 2016 through November 2017, that included 500 customers who were taking Serenol for at least 3 months. Patients were compensated for completing the survey.

  • ¹⁵ Sylla S, et al. Current Developments in Nutrition. 2021; 5:Supplement_2:37.
    ¹⁶ Open-label extension data on file.
    ¹⁷ Kalman & Hewlings. J Clin Exp Dermatol Res. 2021;12:551.